(R)-3-amino-N-(3-(2,4-dichlorophenyl)-1-oxo-1-(4-(2-((2-(thiophen-2-yl)ethylamino)methyl)phenyl)piperazin-1-yl)propan-2-yl)propanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (R)-3-amino-N-(3-(2,4-dichlorophenyl)-1-oxo-1-(4-(2-((2-(thiophen-2-yl)ethylamino)methyl)phenyl)piperazin-1-yl)propan-2-yl)propanamide
• 英文别名: 3-amino-N-[(2R)-3-(2,4-dichlorophenyl)-1-oxo-1-[4-[2-[(2-thiophen-2-ylethylamino)methyl]phenyl]piperazin-1-yl]propan-2-yl]propanamide
• 化学式: C₂₉H₃₅Cl₂N₅O₂S
• 分子量: 588.6
• InChiKey: KKBPPVVSQKSKNV-AREMUKBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  39
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• TREATMENT OF DISEASE OR INJURY OF THE NERVOUS SYSTEM USING AGENTS THAT DECREASE THE ACTIVITY OF THE MELANOCORTIN 4 RECEPTOR
  申请人：Lindquist Per

  公开号：US20100129319A1

  公开（公告）日：2010-05-27

  Novel methods are provided for modulating CNS cell neogenesis in the CNS cells in vitro or in vivo, involving the use of agents that decrease the activity of the melanocortin 4 receptor (MC4R). When the methods of the invention are applied to a subject such as a human, it may be used for reducing a symptom of a CNS disorder.